Lenacapavir HIV Prevention: Gilead’s Stra...

By João L. Carapinha

July 10, 2025

Gilead Sciences has finalized a strategic partnership with the Global Fund. The agreement aims to supply lenacapavir HIV prevention, a twice-yearly inject...
Cell Therapy for Type 1 Diabetes: Vertex Trial Results and Market Potential
Enhertu Reimbursement Analysis: Navigating Cost-Effectiveness Challenges
Alzheimer’s Blood Test Diagnostics: FDA Clears First Blood Test for Ear...
High Orphan Drug Prices Persist Despite Market Exclusivity Expiration
Ivonescimab NMPA Approval Signals Breakthrough in Lung Cancer
Urgent Need for Pediatric Heart Devices
NICE Grants Conditional Robotic Surgery Approval to Enhance Patient Care and ...
Neoadjuvant Immunotherapy Efficacy: Enhancing Treatment Strategies for Head a...
Engineering Resilience: Mastering Pharma Patent Expiration Strategy
Oral Health in Africa: Promoting Collaborative Solutions
Pharmaceutical Innovation and Market Access: Insights from Fast Company’s 202...
Maternal Child Health in South Africa